Market Place
Sourcing Support
Layoffs at Meissa Vaccines as biotech`s future lies in limbo
05 Mar 2024 //
FIERCE BIOTECH
Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine
08 Aug 2023 //
BUSINESSWIRE
Meissa Vaccines Announces Positive Data for Intranasal Live Attenuated RSV
07 Nov 2022 //
BUSINESSWIRE
Meissa Presented at The White House Summit on Future of COVID-19 Vaccines
27 Jul 2022 //
BUSINESSWIRE
Meissa Vaccines Appoints Frank Glavin Chief Executive Officer
11 Jul 2022 //
BUSINESSWIRE
Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity
28 Oct 2021 //
BUSINESSWIRE
Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine
20 Jul 2021 //
BUSINESSWIRE
Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine
19 Jul 2021 //
BUSINESSWIRE
Meissa Announces IND Clearance for Phase 1 Study of Intranasal Live
16 Mar 2021 //
PIPELINEREVIEW
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated
21 Jan 2021 //
BUSINESSWIRE
Meissa Vaccines Provides a Pipeline Update on Vaccine for COVID-19 and RSV
30 Jun 2020 //
PIPELINEREVIEW
Meissa Vaccines Receives U.S. FDA Fast Track Designation for, MV-012-968
10 Jan 2020 //
BUSINESS WIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.